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Brief Summary. Despite increases in hepatitis C virus (HCV) among pregnant women, the Society of 
Maternal-Fetal medicine only recommends risk-based screening.  We find HCV screening among pregnant 









niversity of Bristol Library,  natasha-m
artin@




Background: Hepatitis C Virus (HCV) chronic prevalence among pregnant women in the United States 
(U.S.) U.S. doubled nationally from 2009-2014 (~0.7%), yet many remain undiagnosed. Screening 
pregnant women is not recommended by the Society of Maternal-Fetal Medicine or the Centers for Disease 
Control and Prevention, despite new AASLD/IDSA guidelines recommending screening this group.  We 
assessed the cost-effectiveness of HCV screening for pregnant women in the U.S.  
Methods: An HCV natural history Markov model was used to evaluate the cost-effectiveness of universal 
HCV screening of pregnant women followed by treatment after pregnancy compared to background risk-
based screening from a health care payer perspective. We assumed 0.73% HCV chronic prevalence 
among pregnant women based on national data.  We assume no Medicaid reimbursement restrictions by 
fibrosis stage at baseline, but explore differing restrictions in sensitivity analyses. We assessed cost (in 
USD$) and health outcomes (in quality-adjusted life years, QALYs) over a lifetime horizon, using new HCV 
drug costs of $25,000/treatment. We assess mean incremental cost-effectiveness ratios (ICERs) under a 
willingness to pay threshold of $50,000/QALY gained. We additionally evaluate potential population impact. 
Results: Universal antenatal screening was cost-effective in all treatment eligibility scenarios (mean ICER 
<$3,000/QALY gained). Screening remained cost-effective at 0.07% prevalence, the lowest estimated 
prevalence state in the U.S. (Hawaii). Screening the ~5.04 million pregnant women in 2018 could result in 
detection and treatment of 33,000 women based on current fibrosis restrictions. 
Conclusions: Universal screening for HCV among pregnant women in the U.S. is cost effective and should 
be recommended nationally. 
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Hepatitis C virus (HCV) infection among pregnant women doubled in the United States (U.S.) from 2009-
2014, reaching 8% in rural Tennessee.(1) Roughly 0.7% of pregnant women have chronic HCV infection in 
the U.S.(2), equating to ~42,000 pregnancies and 29,000 births among HCV-infected women annually. 
Despite the availability of highly-effective (>90% cure) HCV direct-acting antivirals (DAAs)(3), the majority 
of these women remain undiagnosed and unlinked to care.  
 
Currently, there is disagreement about HCV screening among pregnant women in U.S. clinical guidelines. 
Recent Society of Maternal-Fetal Medicine (SMFM) and American College of Obstetrics and Gynecology 
(ACOG) guidelines reaffirmed recommendations for risk-based testing only for HCV among pregnant 
women.(4) Similarly, the U.S. Center for Disease Control (CDC) recommends routine screening for HIV, 
hepatitis B virus, and syphilis, but not for HCV among pregnant women.(5) By contrast, recent 
AASLD/IDSA guidelines recommend HCV screening for all pregnant women, ideally at the initiation of 
prenatal care.(6) Additionally, in April 2018, the Kentucky legislature recommended testing pregnant 
women due to high burden in that state.(7) For many women, pregnancy is one of their few contact points 
with health care, and a time of health insurance coverage, and as such pregnancy could provide a critical 
opportunity for reaching this population. To our knowledge, no study has evaluated the cost-effectiveness 
of HCV screening in pregnant women in the DAA era in the U.S. 
 
To inform HCV screening policy and practice, we assessed the cost-effectiveness of universal HCV 
screening among pregnant women in the U.S., followed by treatment after pregnancy as determined by 
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Overview: We performed a cost-effectiveness analysis of universal HCV screening among pregnant 
women in the U.S. compared to background risk-based screening from a public sector health care payer 
perspective. Our cost-effectiveness analysis includes long-term health benefits among pregnant women 
only, but we additionally examine potential impact in terms of HCV diagnoses among children born to HCV 
infected mothers in the “”Estimation of Impact” section.  
 
Baseline and comparator: We explored the cost-effectiveness of HCV antenatal screening followed by 
treatment after pregnancy compared to background risk based screening. Our main analysis explores the 
cost-effectiveness in a setting with no treatment restrictions by fibrosis stage but we additionally explore 
scenarios with differing treatment eligibility (see sensitivity analyses).  
 
Model. We utilized a deterministic HCV natural history closed cohort Markov model of HCV disease 
progression and treatment among pregnant women attending antenatal clinics (Figure S1). The population 
was stratified by HCV infection stage, and HCV diagnosis and follow-up status. We assumed all individuals 
become diagnosed and under follow-up upon progression to decompensated cirrhosis or hepatocellular 
carcinoma due to clinical severity. We incorporate loss-to-follow-up among diagnosed women; individuals 
lost to follow-up were eligible for retesting in the community. Individuals who attained SVR with METAVIR 
F3 or lower were assumed not to progress further for HCV, whereas those with F4 or beyond progress at a 
lower rate compared to their HCV-infected counterparts. Individuals whose treatment failed were not 
retreated.  
 
Cost-effectiveness methods. Cost (in 2018 USD $) and health utilities (in quality-adjusted life years, 
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performed a probabilistic uncertainty analysis where parameters were randomly sampled from probabilistic 
distributions (Table 1) to generate 10,000 parameter sets. For each parameter set, the model was run and 
outputs generated.  We calculated the mean incremental cost-effectiveness ratios (ICER, $/QALY gained, 
mean incremental costs divided by the mean incremental QALYs) for the antenatal screening compared to 
background risk-based screening for each treatment eligibility scenario, assessing cost-effectiveness under 
a willingness to pay threshold of $50,000/QALY gained.(8)  
 
Sensitivity Analyses on Cost-effectiveness Results. Due to state differences in Medicaid 
reimbursement policies by fibrosis stage, we additionally examine scenarios where treatment is restricted 
until an individual reaches METAVIR stage F1 or beyond (F1+), METAVIR stage F2 or beyond (F2+), 
METAVIR stage F3 or beyond (F3+), each compared to background screening. In these restriction 
scenarios, women with chronic HCV infection are eligible for treatment upon progression to these disease 
stages if they remain linked to care.  
Additionally, for each treatment eligibility scenario, we perform numerous one-way sensitivity 
analyses.  Due to state variability in HCV chronic prevalence among pregnant women(1), we examined the 
impact of varying HCV prevalence. We additionally performed one-way sensitivity analyses to examine how 
the ICER changed with alterations in: SVR (85% and 95% versus 90% at baseline), age at pregnancy (22 
or 32 compared to 27 at baseline), HCV treatment costs  ($75,000 versus $25,000 at baseline), HCV 
treatment delivery costs ($625 USD versus $1,249 at baseline), proportion previously diagnosed and under 
follow-up (40% compared to 18% at baseline), discount rate (0% for costs and health utilities, or 3% for 
utilities and 6% for costs, versus 3% for each at baseline), liver transplantation costs (50% or 200% 
baseline costs), loss-to-follow up rate per year (10/30/50% per year compared to 12% at baseline), 
background testing rate (10% or 0% per year, compared to 5% at baseline), baseline fibrosis stage 
distribution (3% cirrhosis versus 10% at baseline) and HCV screening uptake (85% based on HBV testing 
uptake among pregnant women, compared to 100% at baseline).(9) Additionally, our baseline fibrosis 
progression rate among U.S. women produced 15% cirrhosis or more advanced liver disease at 20 years, 
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at 35 years for treatment naïve women(10)), so we evaluated a scenario with lower fibrosis progression 
rates.  
 
Estimation of U.S. Population Impact: We additionally estimated the national impact of implementing 
HCV screening of pregnant women in 2018. Due to state heterogeneity in fibrosis restrictions, we first 
generated state-level estimates of the number of pregnant women in a given year (number of births + 
number of fetal losses + number of abortions). (11-13) We estimated births and abortions by multiplying the 
number of women aged 15-44 in a given state by the state-specific birth rate and abortion rate, 
respectively. We estimated fetal losses using the national fetal loss rate based on CDC recommendations 
due to state-level differences in fetal loss reporting by gestational age.(11) As 2016 estimates indicate only 
1.6% of women do not access any prenatal care during pregnancy, we assumed for simplicity all women 
are eligible for screening (14). Based on state-level estimates of pregnant women in 2018 and state fibrosis 
restriction(15), we multiplied the number of pregnant women by HCV identification and treatment rates 
generated from the economic model for each fibrosis restriction scenario assuming the national HCV 
prevalence among pregnant women.  We summed state-level estimates to generate a national estimate of 
the total and incremental number of pregnant women identified and treated with HCV antenatal screening. 
We also estimated the total and incremental number of HCV-infected children born who would be identified 
through follow-up screening based on maternal diagnosis during pregnancy. For this analysis, we assumed 
a vertical HCV transmission rate of 5.8% from a recent meta-analysis.(16) Follow-up testing rates among 
children born to HCV-infected mothers are uncertain, but a recent study(17) found few (16%) children born 
to known HCV-infected mothers were tested at 18 months as recommended by AASLD and pediatric 
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Baseline Population Characteristics. The baseline population included pregnant women with an average 
age of 27 years (based on the median age of reproductive-aged women in the U.S.).(2) We assumed a 
chronic HCV prevalence among pregnant women of 0.73% (95%CI: 0.71-0.75%) based on national 
estimates(2), corresponding to an anti-HCV prevalence of 1.11%, given 34% spontaneous clearance in 
women.(9)  We assumed a chronic HCV prevalence among people who inject drugs (PWID) of 52% (range 
43-60%) based on national estimates.(18, 19) HCV fibrosis distribution was based on U.S. national 
estimates for women.(20)  
Estimates of the proportion of HCV-infected pregnant women diagnosed and currently under follow-
up for HCV are unknown.  The 2008 NHANES survey estimated 50% of HCV-infected individuals were 
diagnosed, but this was lower among young individuals (29% for age <40).(21) Updated estimates indicate 
the overall proportion diagnosed has increased by a relative 10% (from 50% in 2008 to 55% in 2017).(22) 
Based on this, we assumed 32% of pregnant women are currently diagnosed based on estimates among 
individuals age <40 (29% in 2008, estimated increase by relative 10% in 2017). We note that one study 
among HCV-infected pregnant women on opiate substitution therapy (OST) found 70% were previously 
diagnosed, but it is likely this would overestimate the proportion of all HCV-infected women diagnosed, and 
unclear how many were under follow-up.(23) Linkage to HCV care rates similarly vary, with recent 
estimates of 34% linkage within 6 months among individuals on OST(24) and 55% among patients 
receiving care in an outpatient clinic.(25)  For this analysis, we estimated 18% of infections among 
pregnant women were diagnosed and linked (32% diagnosedx55% linked).  We assumed 12%/year loss to 
follow-up after diagnosis based on data from pregnant women on OST.(26) 
 
Disease Stage Transition Probabilities and Costs. Estimates of stage-specific transition rates among 
women were obtained from published studies.(27) Background (non-hepatitis C related) mortality was time-
varying, based on age-specific mortality rates obtained from WHO life tables.(28) Individuals with F0-F3 
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with cirrhosis or more advanced disease who achieved SVR could progress at a reduced rate (Table 
1).(29, 30) We incorporated HCV disease-related costs from published literature.(31-33)  
 
HCV testing costs: We incorporated costs of anti-HCV and HCV RNA confirmatory testing based on the 
2018 National Fee Schedule.(34) We assume individuals are screened first for anti-HCV, and if found 
positive are then screened for HCV RNA. Outpatient visit consultation costs were included for each testing 
visit.(35) For individuals who are RNA positive, we incorporate liver elastography costs for disease staging. 
 
HCV treatment efficacy and costs: We assumed a baseline direct-acting antiviral (DAA) treatment efficacy 
(i.e. rate of sustained virological response [SVR]) of 90% for all genotypes.(3)  We assumed drug costs for 
DAAs of $25,000 per treatment course (based on the wholesale acquisition cost of glecaprevir/pibrentasvir 
and the price of generic sofosbuvir/ledipasvir and sofosbuvir/velpatasvir available in January 2019).(36) 
Cost components of treatment delivery (pre-treatment and on-treatment monitoring) were based upon the 
IDSA guidelines(3) and the 2018 Clinical Diagnostic Laboratory Fee Schedule(34) (Appendix Table S1). 
 
Utilities. Health utilities (in quality adjusted life-years, QALYs) were obtained from previous published 
studies(37-39). Consistent with other analyses, we assumed a 0.05 incremental increase in health utility for 
patients who achieved SVR(40).  
 
RESULTS 
Cost-effectiveness: Universal HCV screening for pregnant woman was associated with incremental costs 
of $53.2 (95%I -102-174) and incremental increase in QALYs of 0.019 (95%I 0.010-0.028) per pregnant 
woman screened compared to background risk-based screening (Table 2). HCV screening for pregnant 
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with a mean ICER $2,826 per QALY gained, and fell below the willingness to pay (WTP) threshold of 
$50,000 per QALY, gained for 100% of simulations.  
 
Screening remained cost-effective for all the alternative treatment eligibility scenarios by fibrosis stage 
(mean ICERs of $1,934 $2,026, $2,632 in the METAVIR stage F3+, F2+, and F1+ scenarios, respectively, 
Table 2).  
 
Screening remained cost-effective for chronic HCV prevalences among pregnant women at or above 0.03-
0.04%, varying by treatment eligibility scenario (Figure 1, Appendix Figure S2). Results were robust to all 
sensitivity analyses (Appendix Tables S2-S5). Screening remained cost-effective in all settings with lower 
fibrosis progression rates (21% cirrhosis at 35 years), SVR (85%), higher proportion diagnosed and linked 
at baseline (40%), lower liver transplantation costs ($112,000 per transplant), higher loss to follow-up rates 
(50%/year), higher background testing rates (20%/year), and lower proportion of cirrhosis in the baseline 
cohort (3%).  
 
U.S. Population Impact: Given current state-by-state fibrosis restrictions, we estimate screening of the 
estimated 5.04 million pregnant women in 2018 would result in detection of and treatment of approximately 
33,000 women overall, and an incremental detection and treatment of approximately 7,000 women, with the 
remainder diagnosed and treated later on in their disease. Screening could additionally result in detection 
of and treatment of an estimated 300 children born to mothers infected by HCV, and potentially many more 
if rates of return for 18 month HCV testing for children born to HCV-infected mothers increases from the 
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Our analysis indicates that universal HCV screening among pregnant woman in the U.S. is highly cost-
effective and would be associated with improved detection of HCV among women and their children. Our 
results were robust to variations in state restrictions on reimbursement for HCV treatment. They were 
additionally robust to variations in HCV prevalence; screening pregnant women is likely cost-effective in 
settings with chronic HCV prevalence as low as 0.04%. Comprehensive state-specific data on HCV 
prevalence among pregnant women are unavailable, but it appears likely all are above this threshold. 
Among states reporting maternal HCV infection on infant birth certificates, HCV rates vary substantially by 
state, with the highest at 2.2 per 100 births in Tennessee and the lowest reported was 0.07 per 100 births 
in Hawaii in 2014.(1) If these data are representative of true HCV prevalence among pregnant women, 
screening in the lowest prevalence state (Hawaii) would remain cost-effective.(1) As such, our results 
support calls for a change of SMFM/ACOG and CDC guidelines to recommend universal HCV screening of 
pregnant women (41). Our results also provide additional economic evidence in support of the updated 
AASLD/IDSA guidelines(6) and Kentucky legislation(7) recommending screening pregnant women. 
 
To our knowledge, our study is the first to evaluate the cost-effectiveness of HCV screening among 
pregnant women in the U.S. Our findings conflict with a previous study which found HCV screening among 
pregnant women in the United States not cost-effective,(42) but that study utilized old interferon-based 
treatments with low cure rates. Our findings are consistent with a recent study founding antenatal screening 
in the UK cost-effective with newer interferon-based therapies(43). Our findings are also consistent with 
studies finding HCV screening in the DAA era cost-effective among a variety of U.S. populations such as 
adolescents and young adults in primary care settings(35), in prisons(44), in methadone programs(24), and 
one-time testing strategies in the general population.(45) We note that our results show that screening is 
highly cost-effective (ICER <$3,000), lower than previous analyses primarily because we used new drug 
costs of $25,000/treatment. When we use treatment costs similar to previous analyses, we find similar cost-
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As with all modeling studies, ours was limited by several factors, most notably uncertainty in the underlying 
data. First, there is substantial uncertainty in the proportion of pregnant women previously diagnosed and 
engaged in care, linkage to care rates, and loss-to-follow-up rates among this population in the DAA era. 
However, despite this, our sensitivity analyses indicated results were robust to uncertainty in these and 
other parameters.  
 
Second, we do not simulate changing insurance eligibility over time, but note in some non-Medicaid 
expansion states women can lose their insurance coverage as early as 30 days after giving birth. This 
restriction could limit timely uptake of HCV treatment. Clinical studies are underway examining the safety 
and efficacy of HCV treatment during pregnancy. Treatment during pregnancy could reduce the risk of loss-
to-follow-up or loss of insurance coverage after pregnancy, and potentially prevent vertical transmission.  
Future analyses should explore the health and economic implications of treatment during pregnancy, and 
should incorporate women’s preferences around treatment. For example, among a recent study, only 21% 
of HCV-infected women reported willingness to take DAAs during pregnancy for their individual benefit, but 
60% reported willingness if it reduces perinatal transmission.(46) 
 
Third, our cost-effectiveness evaluation incorporates health benefits among pregnant women only, as the 
outcome of HCV diagnosis during pregnancy on subsequent testing among children is uncertain and 
pediatric management of HCV is changing (with studies evaluating treatment among children as young as 
2). As such, for the cost-effectiveness analysis we neglect additional benefits related to HCV diagnosis and 
management among babies born to women identified with HCV, although we estimate screening could 
identify ~300 children born with HCV as a result of pregnancies in 2018.  Even more impact and economic 
benefits could be accrued due to diagnoses of future children born to these mothers. Unfortunately, data 
indicate subsequent testing and follow-up rates of their babies are low among HCV-diagnosed women,(17) 
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Fourth, we neglect the potential risk of reinfection or population treatment as prevention benefits of 
treatment. It is uncertain but possible a sizeable fraction of HCV-infected pregnant women remain at risk 
after pregnancy. However, our previous models show in settings with 50% chronic prevalence among 
PWID like the U.S., early treatment of people with ongoing injecting drug use is cost-effective and prevents 
0.2-0.8 infections per early treatment, despite the risk of reinfection.(47) As such, including reinfection and 
prevention benefits would likely increase the cost-effectiveness of screening. 
 
Fifth, our estimates for population impact of screening are uncertain as they are based on state-level 
estimates of pregnant women and estimated impact by fibrosis state restrictions, but utilize national 
estimates of HCV prevalence among pregnant women, due to a lack of state-level data.  State fibrosis 
restrictions are continually changing and will affect population impact. Additionally, heterogeneity in HCV 
prevalence among pregnant women by state will affect these estimates, and further epidemiological studies 
are warranted. Nevertheless, we believe our general results indicating the potential sizeable impact of 
screening are robust. 
 
 
In conclusion, our study provides evidence that universal HCV screening of pregnant women in the United 
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Table 1. Model parameters inputs and sources. DC: decompensated cirrhosis, HCC: hepatocellular 
carcinoma, PWID: people who inject drugs, SVR: sustained viral response. 
 
State Transitions HCV Stage Mean sampled value  
(2.5%-97.5% quantiles) 
Sampling distribution Source 
HCV chronic prevalence among 
pregnant women  
 0.73% (0.71- 0.75%) 
 
Uniform Range: 0.709-0.751 (2) 
 
HCV antibody prevalence 
among pregnant women  




Proportion who spontaneously 
clear their acute infection 
 34% (30–38%) Uniform Range: 0.3-0.38 (9) 
Annual loss to follow-up rates 
after HCV diagnosis  
 12% (7-17%) Uniform Range: 0.07-0.17 (26) 
Proportion HCV-infected 
pregnant women previously 
diagnosed and linked to care  
 18% (10-25%) Uniform Range: 0.1-0.26 (21, 22) see 
text 
Background testing and linkage 
rate per year 
 




50% linked to 
care (24) 
HCV chronic prevalence among 
PWID (%) 
 52% (44–59%)  
 
Uniform Range: 43-60 (18, 19) 
Liver disease stage transition 
rate per year 
F0 to F1 0.1125 (0.996-0.1261) Beta (251.2107 1984.813) (27) 
F1 to F2 0.1125 (0.996-0.1261) Beta (251.2107 1984.813) (27) 
F2 to F3 0.1125 (0.996-0.1261) Beta (251.2107 1984.813) (27) 
F3 to F4 0.1125 (0.996-0.1261) Beta (251.2107 1984.813) (27) 
F4 to DC 0.0406 (0.0312-0.0520) 
 
Beta (58.49116 1380.788) (38, 39, 48) 
F4 to HCC 0.0212 (0.0163-0.0276) Beta (52.83443, 2417.472) (38, 39, 48) 
DC to HCC 0.0141 (0.0016-0.0395) Beta (1.9326, 136.1074) (38) 
DC/HCC to 
transplant 
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State Transitions HCV Stage Mean sampled value  
(2.5%-97.5% quantiles) 
Sampling distribution Source 
Proportion who achieve SVR   0.90  Uniform Range: 0.85-0.95 (3) 
Liver-related death rate per year  F4  
 
0.0324 (0.01716- 0.05234) Beta (12.44677 371.1121) (49) 
DC 0.2210 (0.1207- 0.3414) Beta (11.61594 40.93614 ) (49) 
HCC  0.2210 (0.1207- 0.3414) Beta (11.61594 40.93614 ) (49, 50) 
 Transplant 
year 1 




0. 0353 (0.0288- 0.0425)   Beta (97.65551 2665.93) (51) 









Relative risk of progression if 




F4 to DC 
 
 








           F4 to HCC 0.23 (0.16-0.35) Lognormal (-3.37754,1.9534) (29, 30) 
 DC to HCC 1 -  
HCV fibrosis distribution among 
HCV diagnosed women 
 
F0 0.16  (20) 
 F1 0.43   
 F2 0.21   
 F3 0.10   
 F4 0.10   
Cost (all costs inflated to USD$ 
2018 (34)) 
     
Annual costs for non-treatment 
medical expenses among HCV-
infected patients  
F0-F3 $511 ($304-734) Uniform +/- 50% point 
estimate 
(31-33) 
F4 $2,898 ($2,009-3,786) Uniform +/- 50% point 
estimate 
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State Transitions HCV Stage Mean sampled value  
(2.5%-97.5% quantiles) 
Sampling distribution Source 
estimate 























HCV Antibody test (including 
consultation) 
 $39 -- (50, 52)  
 
HCV RNA test (including 
consultation) 
 $52 -- (50, 52)  
 
Liver elastography  $130 -- (50, 52)  
 
HCV antiviral therapy drug cost 
only per treatment course 






Treatment delivery costs per 
course 
 $1,249 ($676-1,853)  Uniform +/- 50% point 
estimate 
(3) Table S1 
Health Utilities     
Uninfected  1  (37) 
HCV-infected patients 
 
F0  0.93 (0.83-1) Beta (59.95413,4.512676) (37, 53, 54) 
F1, F2  0.86 (0.78-0.94) Beta (29.92649,4.871755)  
F3  0.83 (0.78-0.89) Beta (12.30437,2.520171)  
F4  0.81 (0.68-0.89) Beta (41.6698,9.774397)  
DC  0.70 (0.56-0.79) Beta (39.8121,17.06233)  
HCC  0.67 (0.56-0.78) Beta (35.508,17.48901)  
Post-
Transplant 
 0.71 (0.69-0.79) Beta (7.612184,3.109202)  
Incremental increase in health 
utility upon SVR 
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Table 2. Cost-effectiveness results of HCV antenatal versus background screening. ICER: 
Incremental Cost-effectiveness Ratio. QALYs quality adjusted life years. 
 
Scenario 
Cost per person 
(2018 USD $) 
Mean and 2.5-
97.5% Intervals 
Mean QALYs per 




















   
Universal antenatal screening and 
treatment after pregnancy regardless 



















niversity of Bristol Library,  natasha-m
artin@





Figure 1: Impact of HCV chronic prevalence among pregnant women (x axis) on the incremental 
cost-effectiveness ratio (ICER, y axis) of screening pregnant woman compared to background risk-









niversity of Bristol Library,  natasha-m
artin@
ucsd.edu on 31 January 2019
